M
etabolic acidosis results from either the gain of an acid or the loss of a base. The former is due to exogenous or endogenous acid loads resulting in anion gap metabolic acidosis. The latter is due to the loss of a base from either the gastrointestinal or genitourinary tract, producing nonanion gap or hyperchloremic metabolic acidosis.
Renal tubular acidosis (RTA) arises from the kidney's inability to excrete enough acid or retain enough bicarbonate (HCO 3 -), resulting in a clinical syndrome characterized by nongap metabolic acidosis, hyperchloremia, and impaired urinary acidification. In this Core Curriculum, we briefly summarize the role of the kidney in acid-base homeostasis and discuss clinical presentations, diagnoses, and treatments of RTA.
OVERVIEW OF RENAL ACID-BASE HOMEOSTASIS

Total-Body Acid-Base Homeostasis
Metabolism of food particles generates both volatile carbonic acid, which is excreted by the lung, and fixed acid, which is generated primarily from metabolism of proteins. On a Western diet containing high levels of animal protein, an adult generates 15,000 mEq of volatile acid derived from fat and carbohydrate combustion and w1 mEq of fixed acid per kilogram of body weight from metabolism of proteins. This latter is initially neutralized by the body buffers, including HCO 3 -, and then excreted by the kidney. The kidney is therefore responsible for the regeneration of lost buffers through excretion of 1 mEq of hydrogen ion (H 1 ) per kilogram of body weight on a daily basis. It maintains acid-base balance by the reabsorption of all filtered HCO 3 -and the regeneration of HCO 3 -lost through metabolism of food particles. Both processes involve secretion of H 1 , initially to reabsorb filtered HCO 3 -and then to generate new HCO 3 -. The secreted H 1 would either combine with filtered HCO 3 -, resulting in HCO 3 -reabsorption, or combine with urinary buffers in the tubular fluid to be excreted as titratable acids and ammonium ion (NH 4 1 ), thus leading to HCO 3 -regeneration. Net acid excretion (NAE) by the kidney equals the sum of titratable acids and ammonium amounts minus the amount of HCO 3 -:
NAE 5 titratable acids 1 NH 4 1 2 HCO 3 -
The amount of titratable acid is fixed and primarily reflects the amount of phosphate in urine. In contrast, the amount of NH 4 1 produced by the kidney varies greatly, increasing dramatically in acidemic states. Because the amount of titratable acid is fixed, a decrease in NAE is primarily due to either a decrease in NH 4 1 excretion or HCO 3 -loss (see details further in Curriculum). 1 reacts with the luminal HCO 3 -to form carbonic acid, which rapidly dissociates to carbon dioxide, oxygen, and water. This latter reaction is catalyzed by luminal membrane carbonic anhydrase (CAIV). Carbon dioxide generated by this reaction freely enters proximal tubule cells and reacts with water to form carbonic acid, a reaction catalyzed by cytosolic carbonic anhydrase (CAII). Carbonic acid then dissociates rapidly to form HCO 3 -and H
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. HCO 3 -exits through the basolateral membrane by the sodium bicarbonate cotransporter (NBCE1), and H 1 is again available to be secreted into the tubular lumen. The schematic in Fig 1 depicts 1 excretion requires the presence of Rhesus protein, RhCG, which is detected on both the apical and basolateral membrane of most cells of the distal convoluted tubule and intercalated cells of the connecting tubule and collecting duct. It is believed that under normal circumstances, RhCG is the key putative NH 3 transporter expressed in the human kidney and RhBG is expressed at below detectable levels. 
RENAL TUBULAR ACIDOSIS
Based on clinical presentation and pathophysiologic mechanism, RTA is classified into proximal (pRTA or type II), distal (dRTA or type I), and hyperkalemic (or type IV) RTA (RTA type III [ie, combined pRTA and dRTA] is not detailed in this Curriculum because of its rarity).
Proximal RTA pRTA is caused by defective HCO 3 -reabsorption in the proximal tubule (Figs 1 and 3 ). This could be due to defects in H 1 secretion by NHE3 or H 1 -ATPase, impairment of luminal or cytosolic carbonic anhydrase, or defects in the exit of HCO 3 -by the Na 1 /3HCO 3 -cotransporter NBCE1. pRTA could also present as a component of Fanconi syndrome due to generalized impairment of solute reabsorption in the proximal tubule, manifesting as renal loss of glucose, amino acids, phosphate, uric acid, and other organic anions.
Classification of pRTA pRTA can present in hereditary or acquired forms. Hereditary pRTA. Hereditary pRTA may manifest as autosomal recessive, autosomal dominant, or sporadic forms. Patients with autosomal recessive pRTA present with short stature, cataracts, and central nervous system calcification, and the condition is linked to mutations in the Na 1 /3HCO 3 -cotransporter NBCE1 (Fig 1) . In severe forms of pRTA, serum HCO 3 -concentrations , 10 mEq/L and blood pH , 7.1 have been reported. Although inactivation of NHE3 could result in HCO 3 -wasting and pRTA in animal models, mutations in NHE3 causing pRTA in humans have not been reported. Mutations in CAII lead to recessive mixed pRTA and dRTA, or type III RTA, with a predominance of distal acidification defect. Patients with CAII mutations present with HCO 3 -wasting, inability to lower urine pH to ,5.5, 1 is primarily generated in the proximal tubule consequent to the metabolism of glutamine. NH 4 1 transport along the length of the nephron, its absorption in the thick ascending limb, and its secretion into the collecting duct are shown. Abbreviations: CCD, cortical collecting duct; DCT, distal convoluted tubule; G, glomerulus; Gln, glutamine; Glu, glutamate; IMCD, inner medulla collecting duct; NBCE1, sodium bicarbonate cotransporter; OMCD, outer medulla collecting duct; TAL, thick ascending limb. Clinical Presentation and Diagnosis of pRTA. Patients with pRTA can be asymptomatic or could present with weakness/paralysis due to severe hypokalemia and, in rare cases, with bone pain/fracture due to osteomalacia. Hyperchloremic metabolic acidosis in pRTA tends to be milder because distal HCO 3 -reclamation is intact and bicarbonaturia disappears when HCO 3 -load falls below the HCO 3 -tubular maximum (often at serum HCO 3 -level of 14-18 mEq/L). The key laboratory finding is the presence of hyperchloremic metabolic acidosis with hypokalemia and variable urinary pH, with alkaline urine pH if serum HCO 3 -concentration is above the tubular maximum and pH , 5.3 when it is below the tubular maximum. If the diagnosis of pRTA is not clear, urinary pH should be measured after an acid load with ammonium chloride (0.1 g per kilogram of body weight). In patients with pRTA, but not dRTA, urine pH decreases to ,5.3. Because furosemide also decreases urine pH and is easier to use than ammonium chloride, measuring urine pH after the use of furosemide has been suggested in these patients. However, this test has unacceptable rates of false-positive and -negative results. Another approach is to treat patients with HCO 3 -at 1 to 2 mEq/kg/d and check serum HCO 3 -concentration after 2 to 3 weeks. In dRTA, serum HCO 3 -concentration approaches the reference range, whereas it will remain significantly below normal in pRTA and urine will be (or become) markedly alkaline due to HCO 3 -wasting.
Treatment of pRTA
The goal is to increase serum HCO 3 -concentration as close to normal as possible. However, this is often very difficult due to the decrease in HCO 3 -tubular maximum. Oral HCO 3 -at doses of 10 to 15 mEq/kg/d with potassium supplementation is often used. Hydrochlorothiazide may be helpful by increasing the HCO 3 -tubular maximum; however, hypokalemia must be prevented with supplemental potassium and/ or treated. In patients with Fanconi syndrome, phosphate supplementation is often required.
Distal RTA dRTA reflects a failure to reabsorb HCO 3 -by intercalated cells in the collecting duct, resulting in persistent alkaline urine. It is characterized by impaired acid excretion and the inability to reduce urinary pH to ,5.3 when confronted with spontaneous acidemia or acid loading. The defect in H 1 secretion in the collecting duct leads to reduced NAE subsequent to decreased NH 4 1 , titratable acid excretion, and HCO 3 -wasting. This results in a decrease in serum HCO 3 -concentration and generation of hyperchloremic metabolic acidosis. The abnormalities in H 1 secretion in the collecting duct are secondary to defects in H 1 -ATPase, cytosolic CAII, or kidney AE1. NH 4 1 excretion is reduced in dRTA due to impaired trapping of luminal NH 3 in the collecting duct subsequent to defects in H 1 secretion. One unique feature of dRTA is very low urinary citrate levels. This is due to the increase in reabsorption of citrate by the proximal tubule in response to intracellular acidosis.
Classification of dRTA dRTA can be hereditary (primary) or acquired (secondary).
Hereditary dRTA. The vast majority of inherited forms of dRTA are due to defects in AE1 or H 1 -ATPase. In addition, cytosolic CAII gene mutations are associated with a mixed picture of pRTA and dRTA. Mutations in the basolateral Cl -reabsorption in the proximal tubule and collecting duct (mixed dRTA and pRTA). It also affects bone osteoclasts resulting in osteopetrosis.
Acquired dRTA. The most common causes are autoimmune diseases such as Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis, and hypergammaglobulinemia; kidney transplantation; sickle cell disease; and drugs including ifosfamide (more commonly causing pRTA than dRTA), amphotericin B, lithium carbonate, and intravenously administered bisphosphonates such as zoledronate. In Sjögren syndrome, 3% to 6.5% of patients have complete dRTA, whereas up to 33% have incomplete dRTA. A small number have combined dRTA and pRTA, including Fanconi syndrome. A variety of antibodies against H 1 -ATPase, kidney AE1 transporter, and CAII have been reported in these patients. Box 1 summarizes the causes of classical dRTA (type 1).
Clinical Presentation and Diagnosis
Patients with dRTA often present with signs and symptoms related to severe hypokalemia, including proximal muscle weakness, polydipsia, and polyuria. In milder cases, symptoms related to renal calculi may be the first sign of an abnormality in acid secretion. Laboratory studies show hyperchloremic metabolic acidosis with persistent urine pH . 5.3 often associated with hypokalemia. Patients with dRTA and hyperkalemic RTAs have low urinary NH 4 1 (positive urinary anion gap and low urine osmolal gap), whereas patients with hyperchloremic metabolic acidosis due to gastrointestinal HCO 3 -loss (diarrhea) usually have elevated urinary anions (negative urinary anion gap and high urine osmolal gap of more than 300-400 mEq/L). Box 2 shows a summary of urinary NH 4 1 estimation by measuring urinary anion gap and urinary osmolal gap. Figure 4 is a schematic depicting the differential diagnosis of hyperchloremic acidosis (hyperchloremic metabolic acidosis) with respect to the source of HCO 3 -loss (gastrointestinal vs kidney) and the delineating features of serum K 1 concentration, urinary NH 4 1 excretion, and urine pH in distinguishing various types of hyperchloremic metabolic acidosis. The pathophysiology of hyperkalemic RTA (type IV) is discussed in more detail in the following sections.
Treatment of dRTA dRTA, in contrast to pRTA, has a relatively small daily loss of HCO 3 -, often in the range of 1 to 2 mEq/ kg/d. The amount of supplemental sodium or potassium bicarbonate is therefore 1 to 2 mEq/kg/d. In children, normal growth is dependent on an adequate supply of HCO 3 -and maintenance of normal serum HCO 3 -concentration. This often requires an HCO 3 -dose of 4 to 8 mEq/kg/d.
Incomplete dRTA
Incomplete dRTA is defined as having normal serum HCO 3 -concentration while lacking the ability to acidify urine when challenged with an acid-loading test. This should be considered in patients with idiopathic renal calculi with alkaline urine, as well as patients with Sjögren syndrome, children with posterior urethral valve disease, and patients with amphotericin toxicity. Kidney stones are due primarily to low urinary citrate levels combined with a high urine pH (Fig 5) .
Kidney Stones and Nephrocalcinosis in RTA
Kidney stones and nephrocalcinosis are primarily seen in dRTA. The pathogenesis includes low urinary citrate, high urinary calcium, and high urinary pH favoring calcium phosphate precipitation. The use of carbonic anhydrase inhibitors (eg, acetazolamide, topiramate, and zoniramate) results in a similar scenario and is associated with an increased incidence of kidney stones. Patients with pRTA have normal urinary citrate levels and their urinary pH is commonly in an acidic range, protecting against stone formation.
Mechanism of Hypokalemia in pRTA and dRTA
Hypokalemia is a common feature of both pRTA and dRTA. The degree of hypokalemia varies and is often more severe in patients with dRTA. In hereditary dRTA, hypokalemia is a cardinal clinical feature, independent of the genetic mutation, although it is more severe in autosomal recessive forms due to a mutation in subunits of the H 1 -ATPase pump. The mechanism of hypokalemia is only partially understood and involves an increase in aldosterone levels due to sodium wasting, as well as metabolic acidosis. In amphotericin B-induced dRTA, both the impairment in H 1 secretion and K 1 loss are due to a defect in membrane permeability. However, this defect is unique to amphotericin B toxicity and has not been shown in other forms of dRTA. In pRTA, treatment with HCO 3 -supplement will result in marked bicarbonaturia. An increase in urinary HCO 3 -excretion may obligate an increase in K 1 secretion, thereby worsening the hypokalemia. Please refer to Figure 5 . Clinical and laboratory features, pathogenesis, and major complications of incomplete distal renal tubular scidosis (idRTA). Abbreviation: NH 3 , ammonia.
Clinical & laboratory features
• Normal electrolyte with inability to lower urine pH < 5. 1 excretion by measuring urinary anion and/or urinary osmolal gaps (Box 2). Urine pH should be appropriately acidic (pH , 5.5), although pH . 5.5 is seen in obstructive uropathy. Low urinary K 1 excretion can be assessed by a transtubular K 1 gradient or urinary potassiumcreatinine ratio. To establish the cause of hyperkalemic RTA, specific causes including drugs should be sought. When indicated, random serum renin and aldosterone levels are helpful in establishing the diagnosis of hypoaldosteronism, with or without hyporeninism. Urinary obstruction should always be considered when other more common causes have been ruled out. Figure 7 summarizes the distinctive features of pRTA (type II), dRTA (type I), and hyperkalemic RTA (type IV) with respect to their pathogenesis and emphasis on the contrasting presence of nephrocalcinosis and generation of kidney stones, urine citrate, and NH 4 1 excretion.
Treatment of Hyperkalemic RTA The goal of the treatment initially is to normalize serum K 1 concentration because this may improve metabolic acidosis by increasing urinary NH 3 responsible for buffering secreted H 1 , as well as by enhancing HCO 3 -generation in the proximal tubule by enhanced glutamine metabolism (Fig 3) . If this is inadequate, attempts should be made to improve metabolic acidosis. Box 3 discusses long-term treatment of hyperkalemia in patients with hyperkalemic RTA. 
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